A Lancet-published series of articles is examining the health consequences of aging. By and large, the articles emphasize social and economic issues and the importance of growing old more gracefully. But is that all? Are we to focus on going gentle into that good night, or shall we rage (biotechnologically speaking) against the dying of the light?

Poll Question:
How aggressively should biotechnological approaches be used to slow aging or make it more tolerable?

Embrace the idea that aging is a disease. Insist on a cure.

Deploy biotechnology to lessen or eliminate age-related debilities in piecemeal fashion.

Focus on chronic diseases, which afflict everyone. Meeting the practical needs of the elderly is a separate issue.

Beware! Practicing eugenics at the genomic level is inherently risky and puts us on a slippery bioethical slope.

Previous articleCritical Mass of Stem Cells Sets Off Embryonic Development in the Lab
Next articleGVK BIO Picks Up CRO Vanta Bioscience